Vectus Biosystems Limited AI Stock Analysis
Want to see AU:VBS full AI Analyst Report?
Vectus Biosystems Limited (VBS) AI Stock Analysis
Vectus Biosystems Limited
(ASX:VBS)
The score is held down primarily by weak financial performance (zero revenue, ongoing operating losses, and persistent cash burn) and very bearish technical trends (price below all major moving averages with negative momentum). Valuation provides only a modest offset due to a very low P/E, but fundamentals reduce confidence in that signal.
Vectus Biosystems Limited (VBS) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 3.30M
- Dividend Yield
- ―
- Average Volume (3M)
- 51.16K
- Price to Earnings (P/E)
- 1.8
- Beta (1Y)
- 1.23
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Australia
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Vectus Biosystems Limited Business Overview & Revenue Model
Company Description
Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lungs....
Vectus Biosystems Limited Financial Statement Overview
Summary
Overall financial quality is weak: revenue has fallen to zero in 2026 while operating losses persist and cash flow remains consistently negative (free cash flow -573k in 2026). The main offset is a stabilized balance sheet with positive equity (2.32m) and moderate leverage (debt 547k), but the 2026 net profit appears non-operating given negative operating cash flow.
Income Statement
26NegativeBalance Sheet
48NeutralCash Flow
22Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 478.18K | 1.14M | 1.35M | 1.30M |
| Gross Profit | -4,597 | -4,597 | 478.18K | 1.14M | 1.31M | 1.28M |
| EBITDA | -1.36M | -1.36M | -1.69M | -2.27M | -3.19M | -3.28M |
| Net Income | 1.56M | 1.56M | -1.78M | -2.34M | -3.45M | -3.99M |
Balance Sheet | ||||||
| Total Assets | 3.82M | 3.82M | 782.66K | 2.03M | 4.63M | 3.94M |
| Cash, Cash Equivalents and Short-Term Investments | 3.52M | 3.52M | 250.99K | 808.97K | 2.95M | 1.28M |
| Total Debt | 546.66K | 546.66K | 200.00K | 28.93K | 70.21K | 6.90M |
| Total Liabilities | 1.50M | 1.50M | 1.04M | 539.26K | 1.11M | 8.36M |
| Stockholders Equity | 2.32M | 2.32M | -256.62K | 1.49M | 3.52M | -4.42M |
Cash Flow | ||||||
| Free Cash Flow | -573.39K | -573.40K | -830.09K | -2.10M | -2.37M | -4.46M |
| Operating Cash Flow | -573.39K | -573.39K | -830.09K | -2.03M | -2.35M | -4.44M |
| Investing Cash Flow | 0 | 0 | 101.03K | -67.90K | -17.13K | -21.00K |
| Financing Cash Flow | 1.04M | 1.04M | 171.07K | -41.28K | 4.04M | -34.55K |
Vectus Biosystems Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VBS, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.10, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 17.78 is Positive, neither overbought nor oversold. The STOCH value of -0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:VBS.
Vectus Biosystems Limited Peers Comparison
Overall Rating
AU:ACR52Neutral
AU:TRP47Neutral
AU:OCC44Neutral
AU:VBS42Neutral
AU:CMB39Underperform
AU:BOT38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 52Neutral | AUD 5.82M | -6.79 | -45.29% | ― | 290.25% | 92.05% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | AUD 5.86M | -1.24 | -52.04% | ― | 32.22% | -26.53% | |
| 44Neutral | AUD 155.26M | -10.75 | -36.83% | ― | 51.07% | -47.63% | |
| 42Neutral | AUD 3.30M | 1.84 | 206.11% | ― | ― | ― | |
| 39Underperform | AUD 10.60M | -1.43 | -247.44% | ― | -4.24% | 33.39% | |
| 38Underperform | AUD 22.10M | -0.25 | -118.74% | ― | 499.47% | 31.20% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:VBS | Vectus Biosystems Limited | 0.05 | -0.15 | -73.50% | |
| AU:ACR | Acrux Limited | 0.01 | -0.01 | -37.50% | |
| AU:OCC | Orthocell Ltd | 0.57 | -0.41 | -41.84% | |
| AU:TRP | Tissue Repair Ltd | 0.11 | -0.18 | -62.07% | |
| AU:CMB | Regeneus Ltd. | 0.36 | -0.15 | -29.41% | |
| AU:BOT | Botanix Pharmaceuticals Limited | 0.01 | -0.12 | -92.00% |
Vectus Biosystems Limited Corporate Events
Vectus Biosystems Issues 7.9 Million Unquoted Options in New Class
Vectus Biosystems Limited has notified the market of the issue of 7,910,000 unquoted options, each with an exercise price of $0.20 and an expiry date of 30 October 2028. These options constitute a new class of securities that are not quoted and are n...
Vectus Biosystems Secures FDA Pre-IND Pathway for IPF Drug as Cash Position Tightens
Vectus Biosystems reported quarterly progress centred on advancing its lead antifibrotic candidate VB0004 for idiopathic pulmonary fibrosis in the U.S. regulatory system. The company highlighted that the FDA has granted its request for a pre-IND Type...
Vectus Biosystems Wins Unanimous Shareholder Backing at AGM
Vectus Biosystems Limited reported that all resolutions put to shareholders at its Annual General Meeting on 28 October 2026 were passed on a poll, demonstrating unanimous proxy support for each item. The meeting endorsed the re-election of director...
Vectus Biosystems sharpens fibrosis focus as VB0004 advances and partnering strategy gains traction
Vectus Biosystems reported a year of strategic refocusing around the development and commercialisation of its antifibrotic drug library, with lead compound VB0004 progressing on the back of a Phase Ia trial that showed it to be safe and well tolerate...
Vectus wins FDA pre-IND green light for VB0004 in IPF
Vectus Biosystems has secured a pre-Investigational New Drug Type B meeting with the U.S. Food and Drug Administration for its lead antifibrotic candidate VB0004 in idiopathic pulmonary fibrosis. The company, working with Cardinal Health Regulatory S...
Vectus Biosystems sets virtual AGM to ratify capital raising and board re‑election
Vectus Biosystems Limited has called its 2026 Annual General Meeting for 28 October, to be held virtually via Zoom, with shareholders instructed to access the webcast using details provided by the company’s share registrar, Computershare. The AGM wil...
Vectus Biosystems Updates Corporate Governance Framework for 2026
Vectus Biosystems has released its latest corporate governance statement, outlining how it applies the ASX Corporate Governance Council’s principles for the period from 1 July 2025 to 30 June 2026. The company notes that while it aims to comply with...
Vectus Biosystems Releases 2026 Consolidated Annual Report
Vectus Biosystems Limited has released its 2026 annual financial report, covering the consolidated entity and detailing financial statements, notes and the Directors’ declaration in Australian dollars. The report, authorised by the Board of Directors...
Vectus Biosystems Sets Date and Process for 2026 Virtual AGM
Vectus Biosystems has scheduled its 2026 Annual General Meeting for 11:00am Sydney time on 28 October 2026, to be held as a fully virtual event via Zoom for shareholders. The company has also opened the window for director nominations, which must be...
Vectus Biosystems Director Converts Options into Shares, Boosting Equity Stake
Vectus Biosystems Limited has reported a change in director Maurie Stang’s interests, with the exercise of 316,000 zero-priced options into fully paid ordinary shares. Following this transaction on 2 September 2026, Stang’s holdings now include the n...
Vectus Biosystems Issues New Shares to Non-Executive Director Under Incentive Plan
Vectus Biosystems Limited has issued 316,000 new fully paid ordinary shares to Deputy Chairman and Non-Executive Director Maurie Stang, following the exercise of options granted under the company’s Employee Incentive Plan as payment for director fees...
Vectus Biosystems Seeks ASX Quotation for 316,000 New Shares
Vectus Biosystems Limited has applied for quotation on the ASX of 316,000 new ordinary fully paid shares under its existing ticker VBS. The securities, issued on September 2, 2026, arise from the exercise or conversion of options or other convertible...
Vectus Biosystems Sharpens Strategy as VB0004 Takes Centre Stage
Vectus Biosystems has entered a new phase of development in 2025-26, appointing Dr Tara Speranza as chief executive and chief technology officer to sharpen its drug development and commercial strategy. Her appointment is intended to strengthen intern...
Vectus Biosystems Swings to Profit as Revenue Soars and Balance Sheet Strengthens
Vectus Biosystems Limited reported a sharp turnaround for the year to 30 June 2026, with revenues from ordinary activities surging 478.7% to $2.77 million and a consolidated profit after tax of $1.56 million, compared with a restated loss of $1.86 mi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
